1P-LSD

1. 2026-10-19issueIssued emergency
2. 2026-10-19issueIssued info_card
3. 2026-10-19issueIssued notice
4. 2026-09-24srcPharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants
5. 2026-09-24srcAcute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial
6. 2026-09-24srcAbsolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double-Blind, Placebo-Controlled, Crossover Study
7. 2026-09-24srcReturn of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)
8. 2026-09-24srcReturn of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)
9. 2026-09-24srcPharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration
10. 2026-09-24srcAnalytical and behavioral characterization of 1-dodecanoyl-LSD (1DD-LSD)
11. 2026-09-24srcAnalytical and Pharmacological Characterization of 1-(Furan-2-Carbonyl)-LSD (1F-LSD) and Comparison With 1-(Thiophene-2-Carbonyl)-LSD (1T-LSD)
12. 2026-09-24srcGenie in a blotter: A comparative study of LSD and LSD analogues' effects and user profile
13. 2026-09-24srcOpioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects
14. 2026-09-24srcSerotonin toxicity of serotonergic psychedelics
15. 2026-09-24srcIn vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures
16. 2026-09-24srcCrystal Structure of an LSD-Bound Human Serotonin Receptor
17. 2026-09-24srcEffects of tramadol and O-demethyl-tramadol on human 5-HT reuptake carriers and human 5-HT3A receptors
18. 2026-09-24srcHallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases
19. 2026-09-24srcEfficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis
20. 2026-09-24srcPharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD)
21. 2026-09-24srcThe hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors
22. 2026-09-24srcHallucinogen persisting perception disorder: what do we know after 50 years?
23. 2026-09-24srcTolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
24. 2026-09-24srcDirect comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects
25. 2026-09-24srcComparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants
26. 2026-09-24srcAcute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants
27. 2026-09-24srcPharmacological and non-pharmacological predictors of the LSD experience in healthy participants
28. 2026-09-24srcPsychedelics promote plasticity by directly binding to BDNF receptor TrkB
29. 2026-09-24srcKetanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants
30. 2026-09-24srcPharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans
31. 2026-09-24srcPsychedelics
32. 2026-09-24srcREBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics
33. 2026-09-24srcLysergic acid diethylamide: a drug of use?
34. 2026-09-24srcd-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology
35. 2026-09-24srcClinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience
36. 2026-09-24src1P-LSD legal status worldwide: Germany NpSG 2019, UK PSA 2016, US Federal Analogue Act gray area, Canada unscheduled, Australia controlled
37. 2026-09-04issueIssued emergency
38. 2026-09-04issueIssued info_card
39. 2026-09-04issueIssued notice
40. 2026-06-04proposal30 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
41. 2026-06-04publicationPublication — backfill
42. 2026-04-24revisionRevision 1
43. 2026-04-24absenceSearched ClinicalTrials.gov for "1P-LSD lysergamide psychedelic" — no results
44. 2026-04-24genGeneration — pipeline-v5pipeline-v5
45. 2026-04-24rungeneration run

The same entries, as forms: six forms.